Cytokines as Biomarkers of Treatment Response to IFNβ in Relapsing-Remitting Multiple Sclerosis

الملخص EN

Background.

MS patients show a remarkable heterogeneity in their response to disease modifying treatments.

Given the need for early treatment initiation and the diversity of available options, a predictive marker that indicates good or poor response to treatment is highly desirable.

Objective.

To find a biomarker for treatment response to IFNβ among pro- and anti-inflammatory cytokines.

Materials and Methods.

IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10, IL-17A, and TGF-β1 levels were measured in serum and CSF of 43 patients with RR-MS who were followed up for a mean period of 5.3 years.

Thirty-five patients received IFNβ treatment and were divided into good responders (GR, n = 19) and poor responders (PR, n = 16).

The remaining 8 patients showed a very favorable outcome and remained untreated (noRx).

Results.

GR had significantly higher serum baseline levels of IL-17A than PR and significantly higher serum levels of IL-17A, IFN-γ, TNF-α, and IL-2 than noRx.

PR had significantly higher IFN-γ serum levels than noRx.

No significant differences were observed in serum levels of IL-6, IL-4, IL-10, and TGF-β1 or the levels of all cytokines measured in CSF between the 3 groups of patients.

Conclusions.

Baseline serum levels of IL-17A can be used as a biomarker of IFNβ treatment response.